Peanut allergy is common, with recent studies estimating a prevalence of 0.8% in children and an overall prevalence of 0.5% - 1% in the general population, and there is evidence that the prevalence of peanut allergy is rising in both the United States and Europe. Currently, the only treatment for peanut allergy is a peanut-free diet and ready access to self-injectable epinephrine. However, accidental ingestions are common, with up to 50% of food-allergic patients having an allergic reaction over a two-year period. Allergic reactions to peanut can be severe and life threatening, with peanut and/or tree nut allergies accounting for the vast majority of fatal food-induced anaphylaxis. Given these facts, the development of effective therapy for peanut allergy is critical. Over the past several years we have made substantial progress in our understanding of peanut allergy and potential treatment strategies for peanut and other food allergies. Recent studies have shown the potential of oral immunotherapy for the treatment of milk, egg and peanut allergies, but this therapy primarily appears to induce desensitization, and adverse reactions are common, unpredictable and sometimes severe. Consequently, more effective therapies are needed. The goal of this application is to expand upon these preliminary studies to determine which treatment modality is likely to be most effective and potentially applicable to the general population of peanut allergic patients, and to understand the immunologic mechanisms associated with the development of

Public Health Relevance

Peanut allergy now affects up to 1% of the U.S. population and appears to be increasing. The only therapy available for peanut-allergic patients is strict dietary avoidance and treatment of accidental ingestions. Unfortunately accidental ingestions are common and food allergies, especially peanut, account for the majority of anaphylactic reactions seen in American emergency departments. Consequently, it is imperative that some form of immunotherapy be developed to treat this growing problem.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI066738-09
Application #
8505357
Study Section
Special Emphasis Panel (ZAI1-WFD-I)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
9
Fiscal Year
2013
Total Cost
$2,070,536
Indirect Cost
$531,193
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Caubet, Jean-Christoph; Masilamani, Madhan; Rivers, Neisha A et al. (2014) Potential non-T cells source of interleukin-4 in food allergy. Pediatr Allergy Immunol 25:243-9
Jung, YunJae; Rothenberg, Marc E (2014) Roles and regulation of gastrointestinal eosinophils in immunity and disease. J Immunol 193:999-1005
Kottyan, Leah C; Davis, Benjamin P; Sherrill, Joseph D et al. (2014) Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease. Nat Genet 46:895-900
Lim, Eunjin; Rothenberg, Marc E (2014) Demethylation of the human eotaxin-3 gene promoter leads to the elevated expression of eotaxin-3. J Immunol 192:466-74
Sherrill, Joseph D; Rothenberg, Marc E (2014) Genetic and epigenetic underpinnings of eosinophilic esophagitis. Gastroenterol Clin North Am 43:269-80
Jarvinen, K M; Westfall, J E; Seppo, M S et al. (2014) Role of maternal elimination diets and human milk IgA in the development of cow's milk allergy in the infants. Clin Exp Allergy 44:69-78
Sicherer, Scott H; Wood, Robert A; Vickery, Brian P et al. (2014) The natural history of egg allergy in an observational cohort. J Allergy Clin Immunol 133:492-9
Fleischer, David M; Burks, A Wesley; Vickery, Brian P et al. (2013) Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol 131:119-27.e1-7
Wood, R A; Sicherer, S H; Burks, A W et al. (2013) A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy. Allergy 68:803-8
Wood, Robert A; Sicherer, Scott H; Vickery, Brian P et al. (2013) The natural history of milk allergy in an observational cohort. J Allergy Clin Immunol 131:805-12

Showing the most recent 10 out of 35 publications